- Home
- WEA vs XFOR Comparison
WEA vs XFOR Comparison
Compare WEA & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- XFOR
- Stock Information
- Founded
- WEA 2002
- XFOR 2014
- Country
- WEA United States
- XFOR United States
- Employees
- WEA N/A
- XFOR N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WEA Finance
- XFOR Health Care
- Exchange
- WEA Nasdaq
- XFOR Nasdaq
- Market Cap
- WEA 129.0M
- XFOR 118.4M
- IPO Year
- WEA N/A
- XFOR N/A
- Fundamental
- Price
- WEA $10.61
- XFOR $3.37
- Analyst Decision
- WEA
- XFOR Strong Buy
- Analyst Count
- WEA 0
- XFOR 3
- Target Price
- WEA N/A
- XFOR $72.33
- AVG Volume (30 Days)
- WEA 46.1K
- XFOR 146.4K
- Earning Date
- WEA 01-01-0001
- XFOR 05-01-2025
- Dividend Yield
- WEA 7.87%
- XFOR N/A
- EPS Growth
- WEA N/A
- XFOR N/A
- EPS
- WEA N/A
- XFOR 2.16
- Revenue
- WEA N/A
- XFOR $31,364,000.00
- Revenue This Year
- WEA N/A
- XFOR $355.69
- Revenue Next Year
- WEA N/A
- XFOR $140.28
- P/E Ratio
- WEA N/A
- XFOR $1.56
- Revenue Growth
- WEA N/A
- XFOR N/A
- 52 Week Low
- WEA $9.60
- XFOR $3.05
- 52 Week High
- WEA $11.29
- XFOR $34.20
- Technical
- Relative Strength Index (RSI)
- WEA 44.92
- XFOR 22.18
- Support Level
- WEA $10.56
- XFOR $3.05
- Resistance Level
- WEA $10.72
- XFOR $3.41
- Average True Range (ATR)
- WEA 0.16
- XFOR 0.62
- MACD
- WEA -0.02
- XFOR -0.02
- Stochastic Oscillator
- WEA 15.22
- XFOR 8.94
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.